POM-V Prescription Required

Bioestrovet 0.250 mg/ml Solution for Injection for Cattle

Active ingredient: Cloprostenol

Form

Injection

Species

Cattle

Manufacturer

Vetoquinol UK Limited

VMD MA No.

08007/5035

What it's used for

- - corpus luteum. - - -

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Cloprostenol

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Bioestrovet 0.250 mg/ml Solution for Injection for Cattle — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

-
-
corpus luteum.
-
-
-

One dose equals 0.5 mg cloprostenol/animal corresponding to 2 ml of the veterinary
medicinal product per animal.
Oestrus induction and synchronisation:
Administer one dose per animal. When no oestrus symptoms are observed, a second
dose can be administered after 11 days.
Treatment of clinical and subclinical endometritis in the presence of a functional
corpus luteum.:
Administer one dose per animal. If necessary, repeat the treatment 10-14 days later.
Treatment of ovarian luteal cysts:
Administer a single dose per animal.
Induction of parturition:
Administer a single dose per animal, not earlier than 10 days before the expected
date of calving.
Induction of abortion up to day 150 of gestation:
Administer a single dose per animal, between the 5th and the 150th day of gestation.
It is recommended that the vial is not broached more than 10 times and that the
appropriate vial size is used for prevailing usage conditions. Otherwise, automatic
syringe equipment, or a suitable draw-off needle, should be used for the 50 ml and
100 ml vials to avoid excessive puncturing of the stopper.

Do not use in pregnant animals in which the induction of abortion or parturition is not
intended.
Do not administer to induce parturition in animals with suspected dystocia due to
mechanical obstruction or abnormal position, presentation and/or posture of the foetus.
Do not use in animals with compromised cardiovascular function, bronchospasm or
gastro-intestinal dysmotility.
Do not use in cases of hypersensitivity to the active substance or to any of the
excipients.

Cattle (heifers, cows):
Rare
(1 to 10 animals / 10 000
animals treated)
Injection site infection
Very rare
(<1 animal / 10 000 animals
treated, including isolated
reports):
Anaphylaxis
;
Increased respiratory rate
;
Increased heart rate
;
Abdominal pain
, Diarrhoea
3,5
;
Incoordination
;
Lying down
;
Retained placenta
, Metritis
, Dystocia
, Stillbirth
;
Restlessness, Frequent urination
3,5
;
May occur if anaerobic bacteria enter the injection site, especially following
intramuscular injection, and may become generalized. Aggressive antibiotic therapy,
particularly covering clostridial species, should be employed at the first sign of
infection. Careful aseptic techniques should be employed to decrease the possibility
of these infections.
Requiring immediate medical attention. Can be life-threatening.
Cloprostenol may cause effects similar to Prostaglandin F2 activity in the smooth
muscles.
May be caused by induction of parturition. As part of induction of parturition,
depending on the date of treatment versus the date of conception, the incidence of
placental retention may be increased.
In case of occurrence, these effects are observed within 15 minutes post-injection
and usually disappear after one hour.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.

There is a refractory period of four to five days after ovulation when cattle are
insensitive to the luteolytic effect of prostaglandins.
For the termination of gestation, best results are obtained before day 100 of
gestation. Results are less reliable between day 100 and 150 of gestation.

Special precautions for safe use in the target species:
To reduce the risk of anaerobic infections arising from vasoconstriction at the
injection site, injections into contaminated (wet or dirty) skin areas should be avoided.
Thoroughly clean and disinfect injection sites prior to administration.
Do not administer intravenously.
All animals should receive adequate supervision after treatment.
Induction of parturition or abortion may cause dystocia, stillbirth and/or metritis. The
incidence of retained placenta may be increased depending on the time of treatment
relative to the date of conception.
Injection into adipose tissue can result in incomplete absorption of the veterinary
medicinal product.
Cloprostenol may cause effects related to Prostaglandin activity in the smooth
muscles, such as increased frequency of urination and defecation.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
Prostaglandins of the F2α-type, such as cloprostenol, can be absorbed through the
skin and may cause bronchospasm or miscarriage. Care should be taken when
handling the product to avoid self-injection or skin contact.
Pregnant women, women of child-bearing age, asthmatics and people with other
respiratory tract diseases should avoid any contact with the veterinary medicinal
product.
Personal protective equipment consisting of impervious gloves should be worn when
handling the veterinary medicinal product.
Accidental spillage on the skin should be washed immediately with soap and
water.
In case of accidental self-injection or spillage onto skin, seek medical advice
immediately, particularly as shortness of breath may occur, and show the package
leaflet or the label to the physician.
This veterinary medicinal product may cause hypersensitive reactions. People with
known hypersensitivity to chlorocresol should avoid contact with the veterinary
medicinal product.
Wash hands after use.
Special precautions for the protection of the environment:
Not applicable.

The concomitant use of oxytocin and cloprostenol increases the effects on the
uterus.
Do not administer with non-steroidal anti-inflammatory drugs (NSAIDs) since they
inhibit endogenous prostaglandin synthesis.
The concomitant use of progestogens decreases the effect of cloprostenol.

Keep the vial in the outer carton in order to protect from light.
This veterinary medicinal product does not require any special temperature storage
conditions.

Meat and offal: 1 day
Milk: Zero hours

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.